Legal Advantage Investments Inc. Sells 200 Shares of Zoetis Inc. $ZTS

Legal Advantage Investments Inc. trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.0% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 6,550 shares of the company’s stock after selling 200 shares during the quarter. Legal Advantage Investments Inc.’s holdings in Zoetis were worth $1,021,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ZTS. Nova Wealth Management Inc. bought a new position in Zoetis in the first quarter worth about $25,000. 1248 Management LLC bought a new position in Zoetis in the first quarter worth about $27,000. Saudi Central Bank bought a new position in Zoetis in the first quarter worth about $29,000. Cornerstone Planning Group LLC raised its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after buying an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC raised its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of ZTS opened at $141.05 on Friday. The firm’s 50-day simple moving average is $149.24 and its two-hundred day simple moving average is $154.41. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a market cap of $62.51 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 2.26 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the company posted $1.56 earnings per share. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s dividend payout ratio is presently 34.42%.

Analysts Set New Price Targets

ZTS has been the subject of a number of research reports. Argus reissued a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and cut their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $196.71.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.